Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022

Introduction. Prostate cancer (PC), according to the results for 2019, is second most frequently diagnosed malignant tumor in men living Russian Federation. There a significant proportion of patients with advanced (III-IV stages) prostate - up 50 %, while metastatic accounts 18.1 % patients. Popularization Moscow City Healthcare clinical practice innovative technologies managing castration-resistant (mCRPC) directly meets goals and objectives Federal project aimed at increasing life expectancy patients.
 Materials methods. The article reviews developments field mCRPC treatment presented ASCO Annual Meeting, June 3-7, 2022: VISION sub-studies, TheraP study, study prognostic role circulating DNA (ctDNA) early choice strategy use abiraterone or enzalutamide initial naïve status.
 Results discussion. volume information on theranostic antitumor radiation implemented participation prostate-specific membrane antigen (hereinafter referred as PSMA) growing rapidly. PSMA mediated radio-imaging considered potentially effective tool selecting who are sensitive specific therapy. When studying radionuclide therapy by ligand (PSMA-L), main efforts focused determining optimal regimens its application. possibility expanding current indications prescribing 177Lu-PSMA-617 an earlier stage also being studied. Until final obtained from trials that provide clear answers open questions regarding various aspects application technologies, it remains very important reach expert consensus, within framework exchange opinions, re arding their appropriate situations.